ArticleFrontiers in clinical diabetes and healthcare2025
Rationale and protocol for the Time to Move Randomized Crossover Trial: morning versus evening time physical activity and CGM-assessed glucose levels in individuals with pregnancy hyperglycemia.
Article in Frontiers in clinical diabetes and healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06125704 (The Time to Move Randomized Crossover Trial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Time to Move Randomized Crossover Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For most patients with pregnancy hyperglycemia, treatment includes lifestyle behavioral counseling for a healthy diet and physical activity (PA). Outside of pregnancy, emerging evidence suggests that the Objective: To describe the rationale and protocol of the Time to Move Randomized Crossover Trial, which evaluates the effects of morning vs. evening PA on glucose levels across the 24-hour cycle. Methods: The eligibility criteria include singleton pregnancies in patients aged 18-40 years, identified as having gestational glucose intolerance [(GGI), a non-fasted, 50-g glucose challenge test, 1-hour value ≥130 mg/dl] or gestational diabetes mellitus [(GDM), by the one- or two-step procedure, at ≥24 weeks]. Participants who provide consent are randomized to first perform either morning PA (between 5 a.m. and 9 a.m., within 30 min-40 min of starting breakfast) or evening PA (between 4 p.m. and 8 p.m., within 30 min-40 min of starting dinner). All PA episodes consist of 30 min of moderate-intensity walking or stepping. Participants ultimately contribute 2 days in each of the three treatment conditions: morning PA, evening PA, and no PA, with one washout day between treatment conditions. Timestamped glucose measurements are obtained using Dexcom G6 or G7 continuous glucose monitors (CGM). The primary analysis will be intention-to-treat; per-protocol associations will also be explored. PA adherence is assessed using ActiGraph PA monitoring devices (i.e., the CentrePoint Insight Watch, worn on the non-dominant wrist), which provide continuous timestamped estimates of movement. Participants upload photos (i.e., in real time) of all foods and beverages consumed throughout the study period, and the timestamps of these photos are used to identify postprandial periods. One 24-hour dietary recall, aided by photo uploads, is also completed for each treatment condition. Conclusions: The Time to Move Randomized Crossover Trial addresses the gap in scientific knowledge regarding whether the Clinical trial registration: ClinicalTrials.gov, identifier NCT06125704.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.